$TSHA
Taysha Gene Therapies, Inc. Stock $tsha

$tsha Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024033484 Filed on March 19, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.411M	$3.604M	$15.45M
YoY Change	-27.43%	44.04%	518.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.084M	$6.719M	$30.05M
YoY Change	-19.05%	-8.47%	-19.57%
% of Gross Profit
Research & Development	$20.66M	$12.68M	$56.78M
YoY Change	65.07%	-8.51%	-37.72%
% of Gross Profit
Depreciation & Amortization	$300.0K	$366.0K	$1.400M
YoY Change	0.0%	0.55%	16.67%
% of Gross Profit
Operating Expenses	$27.74M	$19.40M	$87.89M
YoY Change	30.45%	-8.49%	-46.72%
Operating Profit	-$24.33M		-$72.44M
YoY Change	46.93%		-55.41%
Interest Expense	$29.00K	$1.208M	$4.998M
YoY Change	-97.89%	-302.35%	31.6%
% of Operating Profit
Other Income/Expense, Net	$269.0K	$64.18M	-$39.13M
YoY Change	-125.31%	-1069716.67%	996.92%
Pretax Income	-$24.06M	$47.74M	-$111.6M
YoY Change	36.54%	-185.68%	-32.8%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$24.06M	$47.74M	-$111.6M
YoY Change	36.54%	-185.68%	-32.8%
Net Earnings / Revenue	-705.39%	1324.67%	-722.06%
Basic Earnings Per Share	-$0.10		-$0.96
Diluted Earnings Per Share	-$0.10	$0.23	-$0.96
COMMON SHARES
Basic Shares Outstanding	187.0M	187.0M	116.1M
Diluted Shares Outstanding	231.2M		116.1M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$124.0M	$143.9M	$143.9M
YoY Change	95.47%	63.79%	63.79%
Cash & Equivalents	$124.0M	$143.9M	$143.9M
Short-Term Investments
Other Short-Term Assets	$149.0K	$292.0K	$5.928M
YoY Change	-71.99%	-34.82%	-30.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$130.6M	$149.9M	$149.9M
YoY Change	80.49%	55.44%	55.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.69M	$10.83M	$20.41M
YoY Change	-27.02%	-27.65%	-21.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$304.0K	$304.0K	$2.455M
YoY Change	-76.9%	-76.9%	-37.9%
Total Long-Term Assets	$22.40M	$22.86M	$22.86M
YoY Change	-23.39%	-23.43%	-23.43%
TOTAL ASSETS
Total Short-Term Assets	$130.6M	$149.9M	$149.9M
Total Long-Term Assets	$22.40M	$22.86M	$22.86M
Total Assets	$153.0M	$172.7M	$172.7M
YoY Change	50.59%	36.79%	36.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.38M	$6.366M	$6.366M
YoY Change	15.31%	-41.84%	-41.84%
Accrued Expenses	$12.42M	$11.21M	$11.21M
YoY Change	-25.2%	-38.72%	-38.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$362.0K	$354.0K	$354.0K
YoY Change	10.37%
Total Short-Term Liabilities	$38.64M	$36.76M	$36.76M
YoY Change	-29.05%	-41.46%	-41.46%
LONG-TERM LIABILITIES
Long-Term Debt	$40.51M	$40.51M	$40.51M
YoY Change	6.16%	6.69%	6.69%
Other Long-Term Liabilities	$1.502M	$1.577M	$20.53M
YoY Change	-62.49%	-61.82%	-16.44%
Total Long-Term Liabilities	$42.01M	$42.09M	$61.04M
YoY Change	-0.36%	-0.03%	-2.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.64M	$36.76M	$36.76M
Total Long-Term Liabilities	$42.01M	$42.09M	$61.04M
Total Liabilities	$99.15M	$97.79M	$97.79M
YoY Change	-14.93%	-21.97%	-21.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$537.1M	-$513.0M
YoY Change	28.16%	27.8%
Common Stock	$2.000K	$2.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.85M	$74.94M	$74.94M
YoY Change
Total Liabilities & Shareholders Equity	$153.0M	$172.7M	$172.7M
YoY Change	50.59%	36.79%	36.79%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$24.06M	$47.74M	-$111.6M
YoY Change	36.54%	-185.68%	-32.8%
Depreciation, Depletion And Amortization	$300.0K	$366.0K	$1.400M
YoY Change	0.0%	0.55%	16.67%
Cash From Operating Activities	-$19.80M	-$16.12M	-$73.02M
YoY Change	-1.92%	-212.89%	-17.39%
INVESTING ACTIVITIES
Capital Expenditures	$140.0K	$17.00K	$3.869M
YoY Change	-96.41%	-99.26%	-81.24%
Acquisitions
YoY Change
Other Investing Activities		$7.000K	-$17.00K
YoY Change		-111.48%	-127.87%
Cash From Investing Activities	-$140.0K	-$10.00K	-$7.352M
YoY Change	-96.41%	-99.58%	-70.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-22.00K	-4.248M	136.4M
YoY Change	-94.05%	-110.2%	161.81%
NET CHANGE
Cash From Operating Activities	-19.80M	-16.12M	-73.02M
Cash From Investing Activities	-140.0K	-10.00K	-7.352M
Cash From Financing Activities	-22.00K	-4.248M	136.4M
Net Change In Cash	-19.96M	-20.37M	56.02M
YoY Change	-18.38%	-138.03%	-191.51%
FREE CASH FLOW
Cash From Operating Activities	-$19.80M	-$16.12M	-$73.02M
Capital Expenditures	$140.0K	$17.00K	$3.869M
Free Cash Flow	-$19.94M	-$16.13M	-$76.89M
YoY Change	-17.22%	-234.81%	-29.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001806310
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#Liabilities
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39536
CY2023	dei	Entity Registrant Name EntityRegistrantName	Taysha Gene Therapies, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3199512
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3000 Pegasus Park Dr
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste 1430
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75247
CY2023	dei	City Area Code CityAreaCode	214
CY2023	dei	Local Phone Number LocalPhoneNumber	612-0000
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.00001 per share
CY2023	dei	Trading Symbol TradingSymbol	TSHA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	30400000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	187018275
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143940000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87880000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	449000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3479000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8537000
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	2000000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	149868000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	96417000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2151000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2637000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10826000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14963000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9582000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10943000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	304000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1316000
CY2023Q4	us-gaap	Assets Assets	172731000
CY2022Q4	us-gaap	Assets Assets	126276000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6366000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10946000
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12284000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18287000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18106000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33557000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36756000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62790000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40508000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	37967000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18953000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20440000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1577000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4130000
CY2023Q4	us-gaap	Liabilities Liabilities	97794000
CY2022Q4	us-gaap	Liabilities Liabilities	125327000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	186960193
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	186960193
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63207507
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63207507
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	587942000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402389000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513007000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-401441000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	74937000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	949000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172731000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126276000
CY2023	us-gaap	Revenues Revenues	15451000
CY2022	us-gaap	Revenues Revenues	2502000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56778000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91169000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30047000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37360000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1065000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	36420000
CY2023	us-gaap	Operating Expenses OperatingExpenses	87890000
CY2022	us-gaap	Operating Expenses OperatingExpenses	164949000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-72439000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-162447000
CY2023	tsha	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	34718000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1398000
CY2023	tsha	Change In Fair Value Of Term Loan ChangeInFairValueOfTermLoan	1538000
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3572000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	249000
CY2023	us-gaap	Interest Expense InterestExpense	4998000
CY2022	us-gaap	Interest Expense InterestExpense	3798000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-47000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39127000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3567000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-111566000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-166014000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.78
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.78
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116121482
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116121482
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43952015
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43952015
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95383000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18275000
CY2022	tsha	Payment Of Sales Commissions And Other Offering Costs PaymentOfSalesCommissionsAndOtherOfferingCosts	392000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	253000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-166014000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	949000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7905000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	68000
CY2023	tsha	Reclassification Of Pre Funded Warrants To Equity Classification ReclassificationOfPreFundedWarrantsToEquityClassification	74342000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-111566000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	74937000
CY2023	us-gaap	Profit Loss ProfitLoss	-111566000
CY2022	us-gaap	Profit Loss ProfitLoss	-166014000
CY2023	us-gaap	Depreciation Depreciation	1371000
CY2022	us-gaap	Depreciation Depreciation	1172000
CY2023	tsha	Research And Development License Expense ResearchAndDevelopmentLicenseExpense	3500000
CY2022	tsha	Research And Development License Expense ResearchAndDevelopmentLicenseExpense	1250000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7905000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18043000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	34718000
CY2023	tsha	Issuance Costs For Pre Funded Warrant Liability IssuanceCostsForPreFundedWarrantLiability	2567000
CY2023	tsha	Non Cash Gain Loss On Extinguishment Of Debt NonCashGainLossOnExtinguishmentOfDebt	-1366000
CY2023	tsha	Non Cash Change In Fair Value Of Term Loan NonCashChangeInFairValueOfTermLoan	1278000
CY2023	tsha	Debt Issuance Costs Expensed Under Fair Value Option DebtIssuanceCostsExpensedUnderFairValueOption	867000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1065000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	36420000
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1182000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1315000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-741000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-906000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6011000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2088000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2295000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7804000
CY2023	tsha	Increase Decrease In Accrued Expense And Other Liabilities IncreaseDecreaseInAccruedExpenseAndOtherLiabilities	-6277000
CY2022	tsha	Increase Decrease In Accrued Expense And Other Liabilities IncreaseDecreaseInAccruedExpenseAndOtherLiabilities	-9323000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15451000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	33557000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73018000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88390000
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3500000
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4250000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3869000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20619000
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-17000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	61000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7352000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24930000
CY2023	tsha	Proceeds From Trinity Term Loan Net ProceedsFromTrinityTermLoanNet	39550000
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	399000
CY2023	tsha	Repayment Of Svb Term Loan RepaymentOfSvbTermLoan	43000000
CY2023	tsha	Proceeds From Issuance Of Common Stock And Prefunded Warrants From Private Placement Net Of Placement Agent Commissions And Other Offering Costs ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsFromPrivatePlacementNetOfPlacementAgentCommissionsAndOtherOfferingCosts	140290000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	387000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	358000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	68000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	253000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-229000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1042000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136393000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52097000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	56023000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61223000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90517000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151740000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	146540000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90517000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143940000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87880000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2600000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2637000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	146540000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90517000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4952000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2775000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	74342000
CY2023	tsha	Allocation Of Proceeds To Success Fee Liability AllocationOfProceedsToSuccessFeeLiability	770000
CY2023	us-gaap	Settlement Of Asset Retirement Obligations Through Noncash Payments Amount SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount	449000
CY2022	tsha	Property And Equipment In Accounts Payable And Accrued Expenses PropertyAndEquipmentInAccountsPayableAndAccruedExpenses	4002000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	23432000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	387000
CY2023	tsha	Issuance Of Warrants In Connection With Private Placement IssuanceOfWarrantsInConnectionWithPrivatePlacement	252000
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2020-02-13
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143900000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">measurement of impairment of long-lived assets, the valuation of the Trinity Term Loans that are carried at fair value, and the allocation of consideration received in connection with the Astellas Transactions. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	142400000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. On March 10, 2023, the California Department of Financial Protection and Innovation closed the Silicon Valley Bank, Santa Clara, California (“SVB”), and appointed the FDIC as receiver. On March 12, 2023, the Treasury Department announced that depositors of SVB will have access to all of their money starting March 13, 2023. On March 14, 2023, the Company regained access to the full amount of its cash that was deposited with SVB. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management continues to believe to be of high credit quality. The Company has not experienced any losses on these deposits.</span></p>
CY2023	tsha	Shelf Registration Term ShelfRegistrationTerm	P3Y
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	600000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	36400000
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	400000
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	3100000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7800000
CY2023Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q4	tsha	Derecognized Build To Suit Lease Asset Presented In Property Plant Equipment DerecognizedBuildToSuitLeaseAssetPresentedInPropertyPlantEquipment	26300000
CY2023Q4	tsha	Derecognized Build To Suit Lease Liability DerecognizedBuildToSuitLeaseLiability	26500000
CY2023Q4	tsha	Deferred Rent Liabiilities And Tenant Improvement Allowances DeferredRentLiabiilitiesAndTenantImprovementAllowances	700000
CY2023Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	200000
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	142425000
CY2023Q4	tsha	Trinity Term Loans TrinityTermLoans	40508000
CY2023Q4	tsha	Success Fee Derivative Liability SuccessFeeDerivativeLiability	800000
CY2023Q4	tsha	Ssi Warrants SsiWarrants	454000
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	41762000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13805000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16605000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2979000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1642000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10826000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14963000
CY2022Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	36400000
CY2022Q4	tsha	Construction In Progress And Finance Lease Right Of Use Asset ConstructionInProgressAndFinanceLeaseRightOfUseAsset	26300000
CY2023	us-gaap	Depreciation Depreciation	1400000
CY2022	us-gaap	Depreciation Depreciation	1200000
CY2023	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-600000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8537000
CY2023Q4	tsha	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3467000
CY2022Q4	tsha	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	8190000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3423000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2519000
CY2023Q4	tsha	Accrued Clinical Trial Current AccruedClinicalTrialCurrent	1851000
CY2022Q4	tsha	Accrued Clinical Trial Current AccruedClinicalTrialCurrent	1473000
CY2023Q4	tsha	Lease Liability Current LeaseLiabilityCurrent	1646000
CY2022Q4	tsha	Lease Liability Current LeaseLiabilityCurrent	1521000
CY2023Q4	tsha	Warrant Liability Current WarrantLiabilityCurrent	454000
CY2023Q4	tsha	Accrued Severance AccruedSeverance	390000
CY2022Q4	tsha	Accrued Severance AccruedSeverance	1463000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	330000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	390000
CY2022Q4	tsha	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	2081000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	723000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	650000
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12284000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18287000
CY2023Q4	tsha	Prepaid Research And Development Contracts PrepaidResearchAndDevelopmentContracts	1412000
CY2022Q4	tsha	Prepaid Research And Development Contracts PrepaidResearchAndDevelopmentContracts	4840000
CY2023Q4	tsha	Prepaid Clinical Trial PrepaidClinicalTrial	802000
CY2022Q4	tsha	Prepaid Clinical Trial PrepaidClinicalTrial	2119000
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	681000
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	724000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	292000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	388000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	292000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	466000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3479000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2770000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2873000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	960000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	452000
CY2023	us-gaap	Lease Cost LeaseCost	3730000
CY2022	us-gaap	Lease Cost LeaseCost	3325000
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M17D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M17D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y5M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1052
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1051
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0772
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2824000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2486000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2810000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	454000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2910000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	454000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2485000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	325000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2577000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	73000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2673000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17045000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30500000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1306000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10255000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	174000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20245000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1132000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1292000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	354000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18953000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	778000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20245000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1132000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	18709000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	21291000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0700
CY2021Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-08-01
CY2021Q3	tsha	Percentage Of Prepayment Of Facility PercentageOfPrepaymentOfFacility	0.075
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	3000000
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	4900000
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	3700000
CY2022Q4	tsha	Probability Of An Option Exercise ProbabilityOfAnOptionExercise	0.50
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1652101
CY2022	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod	1923697
CY2022	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod	4775676
CY2022	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod	2267560
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1067682
CY2023	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod	7160375
CY2023	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod	5447757
CY2023	tsha	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod	4382425
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7162725
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.85
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	0.15
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee	1800
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7905000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18043000
CY2023Q4	tsha	Common Stock And Warrants Fair Value Disclosure CommonStockAndWarrantsFairValueDisclosure	149953
CY2023	tsha	Change In Fair Value Of Warrants ChangeInFairValueOfWarrants	34718000
CY2023Q4	tsha	Warrant Liability Fair Value Disclosure WarrantLiabilityFairValueDisclosure	454000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-111566000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-166014000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116121482
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116121482
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43952015
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43952015
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.78
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.78
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	23216000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1020000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	689000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	3978000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4888000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4607000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8227635
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7501416
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.15
CY2023	tsha	Excise Tax Rate Percentage ExciseTaxRatePercentage	0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0033
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.1898
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0491
CY2023	tsha	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0067
CY2022	tsha	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0055
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.081
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2561
CY2023	tsha	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiability	-0.0655
CY2022	tsha	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiability	0
CY2023	tsha	Effective Income Tax Rate Reconciliation Change In Fair Value Of Term Note EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTermNote	-0.003
CY2022	tsha	Effective Income Tax Rate Reconciliation Change In Fair Value Of Term Note EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTermNote	-0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0293
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47373000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	45609000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1961000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2585000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3647000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	22497000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15563000
CY2023Q4	tsha	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4452000
CY2022Q4	tsha	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4574000
CY2023Q4	tsha	Deferred Tax Assets Impairment Of Long Lived Assets DeferredTaxAssetsImpairmentOfLongLivedAssets	5509000
CY2022Q4	tsha	Deferred Tax Assets Impairment Of Long Lived Assets DeferredTaxAssetsImpairmentOfLongLivedAssets	5525000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	94263000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103431000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2224000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2308000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	47000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2226000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2355000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92037000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101076000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-9000000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	42800000
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	217900000
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	federal NOLs are subject to an annual utilization limitation of $3.1 million, which can be increased in the five year period post change date for any realized built-in gain.
CY2023Q4	tsha	Operating Loss Carryforward Annual Limitation Amount OperatingLossCarryforwardAnnualLimitationAmount	3100000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	27100000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000
CY2023	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0000950170-24-033484-index-headers.html	Edgar Link	pending
0000950170-24-033484-index.html	Edgar Link	pending
0000950170-24-033484.txt	Edgar Link	pending
0000950170-24-033484-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img38674483_0.jpg	Edgar Link	pending
img38674483_1.jpg	Edgar Link	pending
img38674483_2.jpg	Edgar Link	pending
img38674483_3.jpg	Edgar Link	pending
img38674483_4.jpg	Edgar Link	pending
img38674483_5.jpg	Edgar Link	pending
img38674483_6.jpg	Edgar Link	pending
img38674483_7.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsha-20231231.htm	Edgar Link	pending
tsha-20231231.xsd	Edgar Link	pending
tsha-ex23_1.htm	Edgar Link	pending
tsha-ex31_1.htm	Edgar Link	pending
tsha-ex31_2.htm	Edgar Link	pending
tsha-ex32_1.htm	Edgar Link	pending
tsha-ex32_2.htm	Edgar Link	pending
tsha-ex97_1.htm	Edgar Link	pending
tsha-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSHA
Taysha Gene Therapies, Inc. Stock $tsha

2024 Q1 Form 10-K Financial Statement

#000095017024033484 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSHA Taysha Gene Therapies, Inc. Stock $tsha

2024 Q1 Form 10-K Financial Statement

#000095017024033484 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSHA
Taysha Gene Therapies, Inc. Stock $tsha